Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 04-26-2005, 03:11 PM   #1
*_Christine MH_*
Posts: n/a
Not clear when this will happen, but here is the info so you'll know what it is when you see it. Hacettepe is in Turkey, but the Dr Altundag also seems to have a Texas address as well.

"Killed Mycobacterium vaccae may augment the efficacy of trastuzumab in metastatic breast cancer patients.

"SRL172, non-specific immunological adjuvant downregulates interleukin (IL)-4, upregulates IL-2 production, switching towards a T-helper-1 response, induces an increase in natural killer cells and activates antigen presenting cells. The human epidermal growth factor receptor 2 gene amplification is frequently observed in a number of primary tumors, suggesting that the overexpression of this growth factor receptor may contribute to transformation and tumorigenesis. Gene amplification occurs in (approx)15-20% of human breast cancers. Amplification is associated with aggressive tumor behavior and shortened survival," researchers in Turkey, the United States, and Japan report.

"Trastuzumab, humanized anti-HER-2 antibody, targets the HER-2 protein with high affinity," said Kadri Altundag at Hacettepe University and collaborators in Turkey, the United States, and Japan. "Trastuzumab when used alone or in combination with cytotoxic chemotherapy can induce reasonably durable remissions in a significant percentage of women with metastatic breast cancer whose tumors demonstrate Her-2/neu gene amplification. One of the proposed mechanisms of trastuzumab antitumor action is through antibody-dependent cellular cytotoxocity."

"Pivotal study showed that trastuzumab + IL-2 resulted in NK cell expansion with enhanced in vitro targeted killing of HER-2-expressing cells," reported the scientists. "SRL172 by increasing IL-2 production and number of natural killer cells may augment the efficacy of trastuzumab in metastatic breast cancer patients. SRL 172 increases IL-2 production and the number of NK cells in vivo. Based on these data, a clinical trial can be performed to test whether SRL 172 added to trastuzumab is safe and more efficacious."

Altundag and associates published their study in Medical Hypotheses (SRL 172 (killed Mycobacterium vaccae) may augment the efficacy of trastuzumab in metastatic breast cancer patients. Med Hypotheses, 2005;64(2):248-251)."
  Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump

All times are GMT -7. The time now is 01:47 PM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2019, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter